Galen expands product portfolio with GelX® Oral Spray
April 21, 2022
Galen, a global pharmaceutical company, and part of the Almac Group headquartered in Craigavon, has announced a new partnership with Sunstar Suisse S.A. to exclusively distribute and commercialise GelX® Oral Spray in the United Kingdom and Ireland.
GelX® OralSpray is a product designed to treat Oral Mucositis (OM), a painful inflammation of the lining of the mouth and throat often caused by radiation and chemotherapy cancer treatments.1 OM increases the likelihood of infection and puts severely immunocompromised patients at risk of sepsis and septicemia.2 The collaboration with Galen will ensure that this oncology supportive care product is readily available in a hospital setting for direct use by clinicians to improve the quality of life of their patients.
Galen, which has successfully launched over 100 products in more than 25 locations across the world in a range of areas including medical nutrition, pain management, dermatology and gastroenterology, has developed a global expansion strategy of its product portfolio. This partnership extends the company’s UK and Ireland offering to more treatment areas, providing Galen with a growing hospital portfolio which now includes oncology supportive care as well as respiratory disease and Emergency Medicine.
Galen’s Managing Director and President, Dr Dennise Broderick, said: “Galen is recognised as a partner of choice for specialty pharma companies to launch and promote their products within the UK, Ireland, Europe, US and other global regions.”
“We continually invest in building a portfolio of innovative branded products with global potential in existing and new markets. This new partnership with Sunstar Suisse S.A. to supply GelX® Oral Spray, along with the recent announcement of our distribution agreement for Provocholine® (methacholine chloride) are evidence of our ongoing commercial success and expertise.”
- GelX® Oral Spray package leaflet January 2020.
- Al-Dasooqi N. et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013 21:2075-2083.
Established in 1968, Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland), with products in therapy areas including medical nutrition, gastroenterology, pain management and dermatology.
Through organic growth and acquisitions, we have established product sales in 25 locations.
About Almac Group
Galen is a member of the Almac Group. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally.
The international company is a privately owned organisation that has grown organically over the past five decades and now employs over 6,000 highly skilled personnel across 18 facilities including Europe, the US and Asia.
For further information please visit www.almacgroup.com.